[The fibrinolytic activity of the endometrium and myometrium, decidua and placenta and cervical and corpus carcinomas. Physiology, pathology and clinico-therapeutic consequences].
D000614:Aminocaproates / Q000627:therapeutic use; D000933:Antifibrinolytic Agents / Q000627:therapeutic use; D007611:Aprotinin / Q000627:therapeutic use; D046508:Culture Techniques; D003656:Decidua / Q000502:physiology*; D004717:Endometrium / Q000502:physiology*; D005260:Female; D005337:Fibrin / Q000378:metabolism; D005342:Fibrinolysis / Q000502:physiology*; D005831:Genital Diseases, Female / Q000150:complications; D005833:Genital Neoplasms, Female / Q000150:complications; D006470:Hemorrhage / Q000188:drug therapy / Q000209:etiology; D006801:Humans; D008722:Methods; D010920:Placenta / Q000502:physiology*; D011247:Pregnancy; D013916:Thrombelastography; D002583:Uterine Cervical Neoplasms / Q000503:physiopathology*; D014594:Uterine Neoplasms / Q000503:physiopathology*; D014599:Uterus / Q000502:physiology*
D000614:Aminocaproates; D000933:Antifibrinolytic Agents; D005337:Fibrin; D007611:Aprotinin
Die fibrinolytische Aktivität von Endometrium und Myometrium, Dezidua und Plazenta, Kollum- und Korpuskarzinomen. Physiologie, Pathologie und klinisch-therapeutische Konsequenzen.